Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Daria Gaut, Caspian Oliai, Steven Tsai, Chiung-Yu Huang, Joseph Tuscano, Herbert Eradat, Gary J. Schiller

Blood (2022) 140 (Supplement 1): 12735–12736.

https://doi.org/10.1182/blood-2022-157466

Published: 2022

Journal Articles

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Benjamin Heyman, Joseph Tuscano

Blood (2022) 140 (Supplement 1): 4851–4852.

https://doi.org/10.1182/blood-2022-163552

Published: 2022

Journal Articles

Effect of Pesticide Exposure on Non-Hodgkin Lymphoma Incidence and Survival in California

Christina Poh, John D. McPherson, Joseph Tuscano, Qian Li, Arti Parikh-Patel, Christoph F Vogel, Myles Cockburn, Theresa Keegan

Blood (2021) 138 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2021-147012

Published: 2021

Journal Articles

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Tamer Othman, Benjamin Moskoff, Matthew Tenold, Tali Azenkot, Margaret Krackeler, Samantha C Fisch, Laura A. Potter, Paul R. Kaesberg, Jeanna Welborn, Ted Wun, Naseem Esteghamat, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph Tuscano, Brian A. Jonas

Blood (2021) 138 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2021-149276

Published: 2021

Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2021) 138 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2021-148779

Published: 2021

Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141917

Published: 2020

Journal Articles

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Christina Poh, MD, Ebaa Alobeidi, MD, Joseph Tuscano, MD, Aaron S Rosenberg, MD, Rasmus T Hoeg, MD, Brian A Jonas, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-136333

Published: 2020

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Aaron Seth Rosenberg, MD, Qian Li, MS, Ann M Brunson, MS, Joseph Tuscano, MD, Ted Wun, MD, Theresa H.M. Keegan, PhD MS

Blood (2018) 132 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2018-99-117959

Published: 2018

Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Blood (2018) 132 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2018-99-112178

Published: 2018

Journal Articles

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Aaron Seth Rosenberg, MD, Thierry Facon, MD, Safiya Abouzaid, MPH, PharmD, Shankar Srinivasan, PhD, Weiyuan Chung, Kejal Parikh, BSPharm, MS, Joseph Tuscano, MD

Blood (2017) 130 (Supplement 1): 3113.

https://doi.org/10.1182/blood.V130.Suppl_1.3113.3113

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Blood (2016) 128 (22): 2992.

https://doi.org/10.1182/blood.V128.22.2992.2992

Published: 2016

Journal Articles

Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM)

Aaron S Rosenberg, MD MS, Ann M Brunson, MS, Joseph Tuscano, MD, Brian A Jonas, MD PhD, Ted Wun, MD, Theresa Keegan, PhD MS

Blood (2016) 128 (22): 846.

https://doi.org/10.1182/blood.V128.22.846.846

Published: 2016

Journal Articles

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Joseph Tuscano, MD, Ted Wun, MD, Brian Jonas, MDPhD

Blood (2015) 126 (23): 1305.

https://doi.org/10.1182/blood.V126.23.1305.1305

Published: 2015

Journal Articles

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Barbara Marie Galligan, MD, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, MD, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, MD PhD, Neil D. Palmisiano, MD, David F. Claxton, MD, Edward M. Newman, PhD, Joseph Tuscano, MD

Blood (2015) 126 (23): 3977.

https://doi.org/10.1182/blood.V126.23.3977.3977

Published: 2015

Journal Articles

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Brian Jonas, MDPhD, Joseph Tuscano, MD, Ted Wun, MD

Blood (2015) 126 (23): 1991.

https://doi.org/10.1182/blood.V126.23.1991.1991

Published: 2015

NARROW

Trial in Progress: Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at High Risk for Relapse

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Effect of Pesticide Exposure on Non-Hodgkin Lymphoma Incidence and Survival in California

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM)

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only